Evidence map›Paper›PMID 36293067›Full record

ArticleInternational journal of molecular sciences2022

A Comprehensive Assessment of Qualitative and Quantitative Prodromal Parkinsonian Features in Carriers of Gaucher Disease-Identifying Those at the Greatest Risk.

Michal Becker-Cohen, Ari Zimran, Tama Dinur, Maayan Tiomkin, Claudia Cozma, Arndt Rolfs, David Arkadir, Elena Shulman, Orly Manor, Ora Paltiel and 3 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06193421 (An Open-Label Pilot Study for Assessing the Safety and Efficacy of High-Dose Ambroxol), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06193421 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

An Open-Label Pilot Study for Assessing the Safety and Efficacy of High-Dose Ambroxol (HDA) in Newly Diagnosed GBA1 Parkinson Disease (PD)

TypeinterventionalSponsorAgyany Pharma LTDRan2023 to 2025Enrolled40ConditionsParkinson Disease, GBA Gene MutationArmsAmbroxol Hydrochloride
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Olfactory Perception in Parkinson's Disease: The Impact ofInternational journal of molecular sciences · 2025
    Article
  3. Effects ofInternational journal of molecular sciences · 2024
    Article
  4. Skin α-Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease.Movement disorders : official journal of the Movement Disorder Society · 2024
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Michal Becker-CohenGaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Ari ZimranGaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Tama DinurGaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Maayan TiomkinGaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Claudia CozmaCentogene GmbH, 18055 Rostock, Germany.
Arndt RolfsCentogene GmbH, 18055 Rostock, Germany.
David ArkadirFaculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9124001, Israel.
Elena ShulmanGaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Orly ManorBraun School of Public Health and Community Medicine, Hebrew University of Jerusalem, Jerusalem 9124001, Israel.
Ora PaltielBraun School of Public Health and Community Medicine, Hebrew University of Jerusalem, Jerusalem 9124001, Israel.
Gilad YahalomDepartment of Neurology, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Daniela BergDepartment of Neurology, Christian-Albrechts-University of Kiel, 24118 Kiel, Germany.
Shoshana Revel-VilkGaucher Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.ORCID 0000-0001-9151-0337
Hebrew University of Jerusalem · ILShaare Zedek Medical Center · ILCentogene (Germany) · DEChristian-Albrechts-Universität zu Kiel · DE

Funding

Takeda Israel None
6 · The paper itself

Abstract

Carriers of GBA1 gene variants have a significant risk of developing Parkinson’s disease (PD). A cohort study of GBA carriers between 40−75 years of age was initiated to study the presence of prodromal PD features. Participants underwent non-invasive tests to assess different domains of PD. Ninety-eight unrelated GBA carriers were enrolled (43 males) at a median age (range) of 51 (40−74) years; 71 carried the N370S variant (c.1226A > G) and 25 had a positive family history of PD. The Montreal Cognitive Assessment (MoCA) was the most frequently abnormal (23.7%, 95% CI 15.7−33.4%), followed by the ultrasound hyperechogenicity (22%, 95% CI 14−32%), Unified Parkinson’s Disease Rating Scale part III (UPDRS-III) (17.2%, 95% CI 10.2−26.4%), smell assessment (12.4%, 95% CI 6.6−20.6%) and abnormalities in sleep questionnaires (11%, 95% CI 5.7−19.4%). Significant correlations were found between tests from different domains. To define the risk for PD, we assessed the bottom 10th percentile of each prodromal test, defining this level as “abnormal”. Then we calculated the percentage of “abnormal” tests for each subject; the median (range) was 4.55 (0−43.5%). Twenty-two subjects had more than 15% “abnormal” tests. The limitations of the study included ascertainment bias of individuals with GBA-related PD in relatives, some incomplete data due to technical issues, and a lack of well-characterized normal value ranges in some tests. We plan to enroll additional participants and conduct longitudinal follow-up assessments to build a model for identifying individuals at risk for PD and investigate interventions aiming to delay the onset or perhaps to prevent full-blown PD.

Indexed as

Gaucher DiseaseParkinson DiseaseCohort StudiesGlucosylceramidaseHeterozygoteHumansMaleMiddle AgedMutationProdromal SymptomsGlucosylceramidasecarriers of GBA1 variantsGaucher disease carriersParkinson’s diseaseprodromal Parkinson disease

Identifiers

PMID36293067
PMCPMC9603254
OpenAlexW4306152071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.